Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Corinne Franklin – Investor Relations Howard Robin – President and Chief Executive Officer Jonathan Zalevsky – Chief Research and Development Officer Sandra Gardiner – Chief Financial Officer Conference Call Participants Dominic Risso-Gill – Piper Sandler Julian Harrison – BTIG Jay Olson – Oppenheimer Roger Song – Jefferies Mayank Mamtani – B. Riley Securities Arthur He – H.C.
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago.
Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
Nektar Therapeutics (NKTR) came out with quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected.
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Nektar (NKTR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Nektar (NKTR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Vivian Wu - Investor Relations Howard Robin - President & Chief Executive Officer Brian Kotzin - Interim Chief Medical Officer Jonathan Zalevsky - Chief Research & Development Officer Sandra Gardiner - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Julian Harrison - BTIG Jay Olson - Oppenheimer Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Arthur He - H.C.
Down -38.51% in 4 Weeks, Here's Why Nektar (NKTR) Looks Ripe for a Turnaround
Nektar (NKTR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Nektar (NKTR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
